FMI Expresses Disappointment over Administration’s Failure to Address Pharmacy DIR Fees in Final Drug Pricing Rule

ARLINGTON, VA – Food Marketing Institute (FMI) expresses disappointment over a final drug pricing rule released last night that fails to reform pharmacy direct and indirect remuneration (DIR) fees. FMI Director, Food and Health Policy, Peter Matz issued the following statement on behalf of the food retail industry:

“The Administration missed the mark and an opportunity to effectively lower beneficiary out-of-pocket costs, while also stabilizing the operating environment for retail pharmacies. Specifically, DIR fees are being used strategically by pharmacy benefit managers to recoup funds from pharmacies retroactively, often weeks or even months after prescriptions were filled. According to the proposed rule itself, these fees have increased 45,000% in recent years. And, in an industry that operates on razor-thin profit margins, supermarket pharmacies have virtually no ability to absorb these unexpected costs. FMI will be looking at all options, including congressional action, to address the anti-competitive practices that are driving up drug prices and threatening both supermarket pharmacies and the customers they serve.”

About FMI

As the food industry association, FMI works with and on behalf of the entire industry to advance a safer, healthier and more efficient consumer food supply chain. FMI brings together a wide range of members across the value chain — from retailers that sell to consumers, to producers that supply food and other products, as well as the wide variety of companies providing critical services — to amplify the collective work of the industry. www.FMI.org